Want to join the conversation?
$CELG's sales from multiple myeloma drug Revlimid for 2015 increased by 16.5% from last year. This was primarily due to increased unit sales in both U.S. and international markets in addition to price rises in the U.S. market. Increases in market penetration and treatment duration of patients contributed to the increase in U.S. unit sales.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.